No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MRK241220C170000
- 0.00
- 0.000.00%
15min DelayClose Dec 16 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest170.00Strike Price0.00Turnover0.00%IV69.90%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma357.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial
Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion
Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab